T cells engineered to target a shared β-catenin mutation eradicate solid tumors in mice

IF 27.6 1区医学 Q1 IMMUNOLOGY

Nature Immunology Pub Date : 2025-09-10 DOI:10.1038/s41590-025-02287-4

引用次数: 0

Abstract

We identified T cell receptors (TCRs) targeting antigenic peptides that contain a shared β-catenin mutation (CTNNB1S37F) presented on common human leukocyte antigen alleles. TCR-engineered T cells eliminated patient-derived tumors and prevented relapse in vivo in mice, highlighting a strategy to exploit public neoantigens for TCR-based immunotherapy in solid cancers.

Abstract Image

查看原文本刊更多论文

靶向共享β-连环蛋白突变的T细胞可根除小鼠体内的实体肿瘤

我们发现了靶向抗原肽的T细胞受体（TCRs），这些抗原肽含有共同的β-连环蛋白突变（CTNNB1S37F），呈现在常见的人类白细胞抗原等位基因上。tcr工程T细胞消除了患者来源的肿瘤，并防止了小鼠体内复发，突出了利用公共新抗原进行基于tcr的实体癌症免疫治疗的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Immunology 医学-免疫学

CiteScore

40.00

自引率

2.30%

发文量

248

审稿时长

4-8 weeks

期刊介绍： Nature Immunology is a monthly journal that publishes the highest quality research in all areas of immunology. The editorial decisions are made by a team of full-time professional editors. The journal prioritizes work that provides translational and/or fundamental insight into the workings of the immune system. It covers a wide range of topics including innate immunity and inflammation, development, immune receptors, signaling and apoptosis, antigen presentation, gene regulation and recombination, cellular and systemic immunity, vaccines, immune tolerance, autoimmunity, tumor immunology, and microbial immunopathology. In addition to publishing significant original research, Nature Immunology also includes comments, News and Views, research highlights, matters arising from readers, and reviews of the literature. The journal serves as a major conduit of top-quality information for the immunology community.